A detailed history of Parallel Advisors, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Parallel Advisors, LLC holds 252 shares of BNTX stock, worth $25,129. This represents 0.0% of its overall portfolio holdings.

Number of Shares
252
Previous 172 46.51%
Holding current value
$25,129
Previous $13,000 123.08%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$78.36 - $124.66 $6,268 - $9,972
80 Added 46.51%
252 $29,000
Q4 2023

Feb 09, 2024

SELL
$90.91 - $112.75 $727 - $902
-8 Reduced 4.44%
172 $18,000
Q3 2023

May 20, 2024

BUY
$98.5 - $125.08 $3,053 - $3,877
31 Added 20.81%
180 $19,000
Q3 2023

Nov 13, 2023

BUY
$98.5 - $125.08 $3,053 - $3,877
31 Added 20.81%
180 $19,000
Q1 2023

May 20, 2024

SELL
$122.57 - $153.67 $2,819 - $3,534
-23 Reduced 13.37%
149 $18,000
Q1 2023

Apr 25, 2023

SELL
$122.57 - $153.67 $5,883 - $7,376
-48 Reduced 24.37%
149 $18,000
Q4 2022

Feb 03, 2023

SELL
$118.43 - $186.05 $18,356 - $28,837
-155 Reduced 44.03%
197 $29,000
Q2 2022

Aug 01, 2022

BUY
$123.25 - $186.24 $3,697 - $5,587
30 Added 9.32%
352 $52,000
Q1 2022

Apr 28, 2022

SELL
$126.25 - $231.85 $3,913 - $7,187
-31 Reduced 8.78%
322 $56,000
Q4 2021

Jan 20, 2022

BUY
$216.64 - $362.52 $8,232 - $13,775
38 Added 12.06%
353 $91,000
Q3 2021

Nov 02, 2021

SELL
$205.93 - $447.23 $2,059 - $4,472
-10 Reduced 3.08%
315 $86,000
Q1 2021

Apr 23, 2021

BUY
$85.73 - $119.5 $23,575 - $32,862
275 Added 550.0%
325 $35,000
Q4 2020

Feb 02, 2021

SELL
$72.71 - $129.54 $1,817 - $3,238
-25 Reduced 33.33%
50 $4,000
Q2 2020

Jul 16, 2020

BUY
$38.58 - $66.74 $2,893 - $5,005
75 New
75 $5,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $24.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.